Availability of oral antivirals against SARS-CoV-2 infection and the requirement for an ethical prescribing approach
R Dal-Ré, SL Becker, E Bottieau… - The Lancet Infectious …, 2022 - thelancet.com
The first two oral antivirals, molnupiravir and nirmatrelvir–ritonavir, are now becoming
available in many countries. These medicines will be indicated to treat mild-to-moderate …
available in many countries. These medicines will be indicated to treat mild-to-moderate …
[HTML][HTML] Natural tannins as anti-SARS-CoV-2 compounds
Tannins are polyphenols enriched in wood, bark, roots, leaves, seeds and fruits of a variety
of plants. Over the last two decades, there has been an increasing interest in understanding …
of plants. Over the last two decades, there has been an increasing interest in understanding …
Real-world effectiveness of molnupiravir and nirmatrelvir plus ritonavir against mortality, hospitalisation, and in-hospital outcomes among community-dwelling …
Background Little is known about the real-world effectiveness of oral antivirals against the
SARS-CoV-2 omicron (B. 1.1. 529) variant. We aimed to assess the clinical effectiveness of …
SARS-CoV-2 omicron (B. 1.1. 529) variant. We aimed to assess the clinical effectiveness of …
Real-world effectiveness of early molnupiravir or nirmatrelvir–ritonavir in hospitalised patients with COVID-19 without supplemental oxygen requirement on admission …
Background Data on the effectiveness of oral antivirals in patients with mild-to-moderate
COVID-19 are urgently needed. This retrospective cohort study aimed to evaluate the …
COVID-19 are urgently needed. This retrospective cohort study aimed to evaluate the …
Nirmatrelvir, Molnupiravir, and Remdesivir maintain potent in vitro activity against the SARS-CoV-2 Omicron variant
Variants of SARS-CoV-2 have become a major public health concern due to increased
transmissibility, and escape from natural immunity, vaccine protection, and monoclonal …
transmissibility, and escape from natural immunity, vaccine protection, and monoclonal …
An updated practical guideline on use of molnupiravir and comparison with agents having emergency use authorization for treatment of COVID-19
AK Singh, A Singh, R Singh, A Misra - Diabetes & Metabolic Syndrome …, 2022 - Elsevier
Background and aims Molnupiravir is a newer oral antiviral drug that has recently received
emergency use authorization (EUA) in USA, UK and India. We aim to conduct an update on …
emergency use authorization (EUA) in USA, UK and India. We aim to conduct an update on …
A computational comparative analysis of the binding mechanism of molnupiravir's active metabolite to RNA‐dependent RNA polymerase of wild‐type and Delta …
The antiviral drug molnupiravir targets the SARS‐CoV‐2 RNA‐dependent RNA polymerase
(RdRP) enzyme. Early treatment with molnupiravir reduced the risk of hospitalization or …
(RdRP) enzyme. Early treatment with molnupiravir reduced the risk of hospitalization or …
COVID-19, Influenza and RSV: Surveillance-informed prevention and treatment–Meeting report from an isirv-WHO virtual conference
JL McKimm-Breschkin, AJ Hay, B Cao, RJ Cox… - Antiviral Research, 2022 - Elsevier
Abstract The International Society for Influenza and other Respiratory Virus Diseases (isirv)
and the WHO held a joint virtual conference from 19th-21st October 2021. While there was a …
and the WHO held a joint virtual conference from 19th-21st October 2021. While there was a …
Real-world effectiveness of molnupiravir and nirmatrelvir/ritonavir among COVID-19 inpatients during Hong Kong's Omicron BA. 2 wave: an observational study
Background Real-world evidence on the effectiveness of oral antivirals in mild-to-moderate
COVID-19 patients is urgently needed. This retrospective cohort study aims to evaluate the …
COVID-19 patients is urgently needed. This retrospective cohort study aims to evaluate the …
Genetic consequences of effective and suboptimal dosing with mutagenic drugs in a hamster model of SARS-CoV-2 infection
CJR Illingworth, JA Guerra-Assuncao, S Gregg… - Virus …, 2024 - academic.oup.com
Mutagenic antiviral drugs have shown promise against multiple viruses, but concerns have
been raised about whether their use might promote the emergence of new and harmful viral …
been raised about whether their use might promote the emergence of new and harmful viral …